Moderna, Inc. (NASDAQ:MRNA) Holdings Reduced by Lazard Asset Management LLC

Lazard Asset Management LLC trimmed its position in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 81.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,669 shares of the company's stock after selling 11,516 shares during the period. Lazard Asset Management LLC's holdings in Moderna were worth $110,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Letko Brosseau & Associates Inc. boosted its holdings in shares of Moderna by 80.6% in the fourth quarter. Letko Brosseau & Associates Inc. now owns 923,345 shares of the company's stock worth $38,393,000 after acquiring an additional 412,200 shares during the period. Laird Norton Wetherby Wealth Management LLC bought a new position in shares of Moderna in the fourth quarter worth $200,000. Investment Management Corp of Ontario boosted its holdings in shares of Moderna by 125.9% in the fourth quarter. Investment Management Corp of Ontario now owns 24,546 shares of the company's stock worth $1,021,000 after acquiring an additional 13,678 shares during the period. Humankind Investments LLC boosted its holdings in shares of Moderna by 149.2% in the fourth quarter. Humankind Investments LLC now owns 14,427 shares of the company's stock worth $600,000 after acquiring an additional 8,638 shares during the period. Finally, Gotham Asset Management LLC bought a new position in shares of Moderna in the fourth quarter worth $2,670,000. 75.33% of the stock is owned by institutional investors.

Moderna Price Performance

Moderna stock traded up $0.50 during mid-day trading on Tuesday, reaching $26.76. The company had a trading volume of 14,584,904 shares, compared to its average volume of 8,035,353. Moderna, Inc. has a 1 year low of $23.15 and a 1 year high of $164.73. The company has a market capitalization of $10.35 billion, a P/E ratio of -2.88 and a beta of 1.99. The stock's 50-day simple moving average is $26.94 and its 200-day simple moving average is $34.25.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported ($2.52) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.92) by $0.40. Moderna had a negative net margin of 110.04% and a negative return on equity of 28.74%. The company had revenue of $108.00 million during the quarter, compared to analysts' expectations of $130.35 million. During the same period last year, the company posted ($3.07) earnings per share. The firm's quarterly revenue was down 35.3% compared to the same quarter last year. On average, equities analysts forecast that Moderna, Inc. will post -9.61 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. Barclays dropped their price objective on Moderna from $45.00 to $40.00 and set an "equal weight" rating for the company in a research note on Friday, May 2nd. Royal Bank of Canada dropped their price objective on Moderna from $32.00 to $28.00 and set a "sector perform" rating for the company in a research note on Friday, May 2nd. The Goldman Sachs Group downgraded Moderna from a "buy" rating to a "neutral" rating and decreased their price objective for the stock from $99.00 to $51.00 in a report on Wednesday, January 29th. Bank of America decreased their price objective on Moderna from $41.00 to $34.00 and set an "underperform" rating on the stock in a report on Tuesday, February 11th. Finally, William Blair restated a "market perform" rating on shares of Moderna in a report on Thursday, April 17th. Four analysts have rated the stock with a sell rating, fifteen have issued a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $53.58.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.